Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Fosun gets Chinese rights to Bial's PD drug

Elizabeth S. Eaton
January 12, 2018 4:57 PM UTC

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted the Jiangsu Wanbang Biopharmaceutical Group Co. Ltd. subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive, Chinese commercialization rights to Parkinson's disease drug Ongentys opicapone. Bial-Portela will receive €2.5 million ($3 million) up front and is eligible for up to €12.5 million ($15 million) in milestones...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bial-portela & Ca. S.A.

Shanghai Fosun Pharmaceutical Group Co. Ltd.